Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Bennett

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
The Journal of Clinical Investigation|April 20, 2021
Enhanced triacylglycerol catabolism by carboxylesterase 1 promotes aggressive colorectal carcinomaDaria Capece, Daniel D'Andrea, Federica Begalli, et al.
Malaria Journal|January 25, 2013
Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01Nekoye Otsyula, Evelina Angov, Elke Bergmann-Leitner, et al.
Human Vaccines & Immunotherapeutics|August 1, 2013
Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infectionCindy Tamminga, Martha Sedegah, Santina Maiolatesi, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
The Journal of Clinical Investigation|April 20, 2021
Enhanced triacylglycerol catabolism by carboxylesterase 1 promotes aggressive colorectal carcinomaDaria Capece, Daniel D'Andrea, Federica Begalli, et al.
Malaria Journal|January 25, 2013
Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01Nekoye Otsyula, Evelina Angov, Elke Bergmann-Leitner, et al.
Human Vaccines & Immunotherapeutics|August 1, 2013
Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infectionCindy Tamminga, Martha Sedegah, Santina Maiolatesi, et al.
Pageof 6